CN106977561B - Preparation of Sutherlandin-5-p-hydroxybenzoate and application thereof in preparation of drugs for treating rheumatoid arthritis - Google Patents
Preparation of Sutherlandin-5-p-hydroxybenzoate and application thereof in preparation of drugs for treating rheumatoid arthritis Download PDFInfo
- Publication number
- CN106977561B CN106977561B CN201610028681.1A CN201610028681A CN106977561B CN 106977561 B CN106977561 B CN 106977561B CN 201610028681 A CN201610028681 A CN 201610028681A CN 106977561 B CN106977561 B CN 106977561B
- Authority
- CN
- China
- Prior art keywords
- sutherlandin
- hydroxybenzoate
- production method
- compound
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
Abstract
The invention relates to a chemical structure of a compound Sutherlandin-5-p-hydroxybenzoate, a preparation method and application of the compound in preparing a medicament for treating rheumatoid arthritis. Sutherlandin-5-p-hydroxybenazolate is a novel compound purified and prepared from traditional Chinese medicine, namely, pearl plum Sorbaria sorbifolia (L.) A.Brown, by the applicant of the invention, and can obviously inhibit PEG in serum of adjuvant arthritis rats2The tripterygium glycosides with the level of NO and the activity higher than that of tripterygium glycosides with the same dosage can be used for preparing the medicine for treating the rheumatoid arthritis. The chemical structure, the preparation method and the anti-RA activity of the compound are disclosed for the first time, so that the compound has prominent substantive characteristics.
Description
Technical Field
The invention relates to a structure and a preparation method of Sutherlandin-5-p-hydroxybenzoate, and application of Sutherlandin-5-p-hydroxybenzoate in preparing a medicament for treating rheumatoid arthritis.
Background
Rheumatoid Arthritis (RA) is a heterogeneous, systemic, autoimmune disease with symmetric polyarthritis as the main clinical manifestation, and is a highly heterogeneous autoimmune disease under the interaction of environmental factors, genetic background, and both. RA is one of the main reasons for the loss of labor capacity and disability of human beings, the average incidence rate of the diseases is 0.2-1.2% all over the world, and the prevalence rate of China is 0.2-0.93%. The treatment of RA patients requires long-term administration to control the course of disease and improve symptoms, and has high treatment cost and heavy social burden. At present, the drugs clinically used for treating RA mainly comprise non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drugs, biological agents, botanical drug preparations and the like, and although the drugs have certain curative effects, the drugs have strong toxic and side effects, which has a great difference from the ideal antirheumatic drugs which need to be taken for a long time. Therefore, the compound with the anti-RA activity which is safer and more efficient has great value in the aspect of developing RA treatment medicines.
The compound Sutherlandin-5-p-hydroxybenzoate is a new compound purified and prepared from traditional Chinese medicine, namely, pearl plum Sorbaria sorbifolia (L.) A.Brown. The chemical structure, the preparation method and the anti-RA activity of the compound are disclosed for the first time, so that the compound has prominent substantive characteristics.
Disclosure of Invention
The invention provides a preparation method of a novel compound and application of the novel compound in preparing a medicament for treating rheumatoid arthritis.
The invention relates to a compound for preparing rheumatoid arthritis, which is Sutherlandin-5-p-hydroxybenzoate and has the chemical formula: c18H21NO9The structural formula is:
the preparation method of Sutherlandin-5-p-hydroxybenzoate related by the invention comprises the following steps:
taking a medicinal material pearl plum, crushing into coarse powder, adding 20 times of organic alcohol aqueous solution with proper concentration as an extraction solvent, soaking and extracting for 1-3 times, each time being about 10 hours, combining extracting solutions, filtering, dealcoholizing and concentrating until the concentration of the organic alcohol is about 20%, loading the mixture on a macroporous adsorption resin column, eluting 5 column volumes by using about 20% organic alcohol aqueous solution to remove impurities, eluting 4 column volumes by using 50-95% organic alcohol, collecting 50-95% organic alcohol eluting parts, drying under reduced pressure, loading the mixture on a 100-200-mesh silica gel column, selecting a proper silica gel chromatography eluting system to elute, collecting an eluting part containing Sutherlandin-5-p-hydroybenzoate, concentrating, crystallizing and filtering to obtain Sutherlandin-5-p-hydroybenzoate coarse crystals. The crude crystal is dissolved in a recrystallization solvent to form a supersaturated solution, and the solution is recrystallized to obtain a Sutherlandin-5-p-hydroxybenzoate sample with the purity of more than 98%.
The organic alcohol used as the extraction solvent in the process is one of methanol and ethanol, preferably ethanol.
The macroporous adsorption resin column involved in the process is low-polarity or non-polar macroporous adsorption resin, and low polarity is preferred.
The silica gel chromatography elution system related in the process is one or more of dichloromethane, ethyl acetate, n-butanol, methanol and petroleum ether, and a dichloromethane-methanol system is preferred.
The recrystallization solvent involved in the process can be one or more of methanol, ethanol, acetone, ethyl acetate, chloroform and the like, and preferably methanol or ethyl acetate.
The invention also provides application of the compound in preparing a medicament for treating rheumatoid arthritis.
The chemical structure, the preparation method and the anti-rheumatoid arthritis activity of the compound are disclosed for the first time, the possibility of any inspiration given by other compounds does not exist, the compound has prominent substantive characteristics, and the compound is expected to be used for developing a novel anti-rheumatoid arthritis treatment drug.
Drawings
FIG. 1 is a Sutherlandin-5-p-hydroxybenzoate positive ion mass spectrum (HR-ESI-MS).
FIG. 2 is a UV spectrum of Sutherlandin-5-p-hydroxybenzoate (solvent: CD)3OD)。
FIG. 3 is Sutherlandin-5-p-hydroxybenzoate1H NMR Spectrum (solvent: CD)3OD)。
FIG. 4 is Sutherlandin-5-p-hydroxybenzoate13C NMR Spectroscopy (solvent: CD)3OD)。
FIG. 5 is a Sutherlandin-5-p-hydroxybenzoate DEPT spectrum (solvent: CD)3OD)。
FIG. 6 is Sutherlandin-5-p-hydroxybenzoate1H-1H COSY spectrum (solvent: CD)3OD)。
FIG. 7 shows the Sutherlandin-5-p-hydroxybenzoate HMQC spectrum (solvent: CD)3OD)。
FIG. 8 is Sutherlandin-5-p-hydroxybenZoate HMBC Spectroscopy (solvent: CD)3OD)。
FIG. 9 is a Sutherlandin-5-p-hydroxybenzoate NOESY spectrum (solvent: CD)3OD)。
Detailed Description
The following examples are intended to illustrate the invention, but not to limit the substance of the invention.
Example 1 preparation of Sutherlandin-5-p-hydroxybenzoate
Taking a medicinal material of pearl plums, crushing into coarse powder, adding 20 times of 95% ethanol, soaking and extracting for 1-3 times, each time for about 10 hours, combining extracting solutions, filtering, dealcoholizing and concentrating until the ethanol concentration is about 20%, loading the mixture on an AB-8 type weak-polarity macroporous adsorption resin column, eluting 5 column volumes by using 20% ethanol solution to remove impurities, eluting 4 column volumes by using 95% ethanol, collecting 95% ethanol elution parts, drying under reduced pressure, then loading the mixture on a 100-200-mesh silica gel column, taking dichloromethane-methanol as an elution system, carrying out stage elution according to the methanol concentration from low to high, collecting the elution parts with the methanol concentration of 20-30%, concentrating, crystallizing, filtering, drying under reduced pressure, and obtaining sutherland-5-p-hydroybenzoate coarse crystals. And dissolving the coarse crystals in ethyl acetate to form a supersaturated solution, recrystallizing, filtering, and drying under reduced pressure to obtain the product.
Example 2 preparation of Sutherlandin-5-p-hydroxybenzoate
Taking a medicinal material of pearl plums, crushing into coarse powder, adding 20 times of methanol, soaking and extracting for 1-3 times, extracting for about 10 hours each time, combining extracting solutions, filtering, dealcoholizing and concentrating to a proper volume, replenishing water to about 20% of alcohol concentration, loading on a D-101 type nonpolar macroporous adsorption resin column, eluting 5 column volumes by using 20% methanol solution to remove impurities, eluting 4 column volumes by using 90% methanol, collecting 90% methanol elution parts, drying under reduced pressure, loading on a 100-200-mesh silica gel column, taking dichloromethane-methanol as an elution system, carrying out stage elution according to the methanol concentration from low to high, collecting the elution parts with the methanol concentration of 20-30%, concentrating, crystallizing, filtering, and drying under reduced pressure to obtain sutherland-5-p-hydroxybenzoate coarse crystals. And dissolving the coarse crystals in ethyl acetate to form a supersaturated solution, recrystallizing, filtering, and drying under reduced pressure to obtain the product.
Example 3 structural confirmation of Sutherlandin-5-p-hydroxybenzoate
1. Apparatus and materials
Jasco P-1020 digital polarimeter, Agilent TOF/6500 high resolution Mass Spectrometry, Shimadzu UV-2401 visible-ultraviolet Spectrophotometer, Bruke Avance III 500NMR spectrometer, melting point determinator Yanaco MP53 model (melting point uncorrected). Sutherlandin-5-p-hydroxybenzoate samples were prepared as described above in example 1.
2. Structure identification of compounds
Colorless needle crystal (methanol), mp 79-81 deg.C, is easily soluble in dimethyl sulfoxide and methanol, is slightly soluble in ethyl acetate, acetone, chloroform, water, and is insoluble in petroleum ether,
positive ion ESI-MS m/z: 396[ M + H]+，418[M+Na]+(ii) a Negative ion ESI-MS m/z: 394[ M-H]-，430[M+Cl]-，789[2M-H]-. Positive ion HR-ESI-MS m/z: found 418.1104[ M + Na]+Calculated value 418.1114 (C)18H21NO9Na[M+Na]+) (ii) a Negative ion HR-ESI-MS m/z: found 394.1139[ M-H ]]-Calculated value 394.1138 (C)18H20NO9[M-H]-)。UVλmaxnm(logε)in MeOH：259(3.29)，210(3.49)，198(3.52)。1H-NMR(500Hz,CD3OD)δ：7.93(2H,br d,J＝8.8Hz,H-3',7')，6.85(2H,br d,J＝8.8Hz,H-4',6')，5.74(1H,br s,H-2)，5.09(2H,AB type,Ha-5)，4.73(1H,br d,J＝13.6Hz,Ha-4)，4.64(1H,br d,J＝13.6Hz,Hb-4)，4.35(1H,d,J＝7.8Hz,H-1”)，3.88(1H,dd,J＝12.0,2.2Hz,Ha-6”)，3.70(1H,dd,J＝12.0,5.2Hz,Hb-6”)，3.38(1H,t,J＝8.6Hz,H-3”)，3.34(1H,t,J＝8.6Hz,H-4”)，3.30(1H,ddd,J＝9.8,5.2,2.2Hz,H-5”)，3.24(1H,dd,J＝8.6,7.8Hz,H-2”)。13C-NMR(125Hz,CD3OD)δ：167.1(s,C-1')，164.0(s,C-5')，159.8(s,C-3)，133.1(d,C-3',7')，121.4(s,C-2')，116.5(s,C-1)，116.4(d,C-4',6')，104.3(d,C-1”)，97.7(d,C-2)，78.1(d,C-5 "), 78.0(d, C-3"), 74.9(d, C-2 "), 71.4(d, C-4"), 68.4(t, C-4), 64.6(t, C-5), 62.5(t, C-6 "). The NMR data are based on DEPT spectra and1H-1and attributing the two-dimensional spectrum data analysis results of H COSY, HMQC, HMBC and the like. It is concluded from this that the compound structure is:
example 4 preparation of Sutherlandin-5-p-hydroxybenzoate tablets
Taking 10 g of Sutherlandin-5-p-hydroybenzoate, adding a proper amount of 95% ethanol to form an extract, then adding cyclodextrin or porous starch, uniformly mixing to form a soft material, granulating by using a granulator, carrying out vacuum drying, carrying out size stabilization, then adding a lubricant and a flavoring agent, mixing and tabletting, wherein the tablet weight is 250-500 mg, and each tablet contains 5-10 mg of Sutherlandin-5-p-hydroybenzoate.
Example 5 preparation of Sutherlandin-5-p-hydroxybenzoate capsules
Taking 10 g of Sutherlandin-5-p-hydroxybenzoate, adding starch and sodium carboxymethylcellulose, uniformly mixing, and filling into capsules to obtain the compound. Each capsule contains 5-10 mg of Sutherlandin-5-p-hydroxybenzoate.
Example 6 Sutherlandin-5-p-Hydroxybenzoate adjuvant treatment of PEG in serum of arthritis rats2Effect on NO level
1. Apparatus and materials
Ex1800 model enzyme linked immunoassay analyzer (Biotek); UV-2450 type spectrophotometer (Shimadzu, Japan). Bcg, shanghai biologies institute; lanolin, paraffin oil, NO kit and prostaglandin E2(PGE2) The kit is purchased from Nanjing construction reagent company; tripterygium glycosides tablets, Shanghai Compound DAN Fuhua medicinal products, lot number 141001. Wistar rats, SPF grade, female, body mass 120-150 g, provided by Shandong green leaf pharmaceutical laboratory animal center.
2. Modeling and drug delivery
Rats were randomly divided into 4 groups (8 per group) of control, positive control Tripterygium glycosides, model and Sutherlandin-5-p-hydroybenzoate groups. The control group rats were injected with normal saline intradermally into the right hind foot sole, and other groups were injected with 0.1mL of Freund's complete adjuvant (each 10mg of BCG was dissolved in 1mL of paraffin oil, mixed well and autoclaved) intradermally into the right hind foot sole, and the circumference of the left hind foot ankle joint of the rats was recorded. The ig administration of each administration group is started on the 9 th day after the model building, the cyanogen glycoside group and the tripterygium glycosides are both administered according to 10mg/kg, the same amount of normal saline is administered to the model group and the control group, and the administration of each group is continuously performed for 13 d.
3. Index detection
Collecting blood from heart after last administration (21 days after molding) lh, collecting serum, storing at-20 deg.C, and measuring NO and PGE in serum according to kit instructions2The amount of (c). The results are shown in Table 1.
TABLE 1 Sutherlandin-5-p-hydroxybenzoate adjuvant in rats' serum PEG for arthritis2Influence of NO level (
n＝8)
4. And (4) conclusion: sutherlandin-5-p-hydroxybenzoate can obviously inhibit PEG in serum of adjuvant arthritis rat2The tripterygium glycosides with the level of NO and the activity higher than that of tripterygium glycosides with the same dosage can be used for preparing the medicine for treating the rheumatoid arthritis.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be able to cover the technical solutions and the inventive concepts of the present invention within the technical scope of the present invention.
Claims (11)
1. A novel compound, Sutherlandin-5-p-hydroxybenzoate, has the following structural formula:
2. a process for the preparation of the compound of claim 1, characterized by:
pulverizing the medicinal material pearl plum into coarse powder, adding 20 times of organic alcohol water solution with proper concentration as extraction solvent, soaking and extracting for 1-3 times, each time for 10 hours, combining the extracting solutions, filtering, dealcoholizing, concentrating to 20% of organic alcohol concentration, loading to a macroporous adsorption resin column, eluting 5 column volumes by using a 20% organic alcohol aqueous solution to remove impurities, eluting 4 column volumes by using 50-95% organic alcohol, collecting 50-95% organic alcohol elution parts, drying under reduced pressure, loading to a 100-200 mesh silica gel column, selecting a proper silica gel chromatography elution system for elution, collecting an elution part containing sutherland-5-p-hydroxbenzoate, concentrating, crystallizing, filtering, obtaining the crude crystal of Sutherlandin-5-p-hydroxybenzoate, dissolving the crude crystal in a recrystallization solvent to form a supersaturated solution, recrystallizing, the Sutherlandin-5-p-hydroxybenzoate sample with the purity of more than 98 percent can be obtained.
3. The production method according to claim 2, characterized in that: the organic alcohol used as the extraction solvent is one of methanol and ethanol.
4. The production method according to claim 3, characterized in that: the organic alcohol used as the extraction solvent is ethanol.
5. The production method according to claim 2, characterized in that: the macroporous adsorption resin column involved in the process is low-polarity or non-polar macroporous adsorption resin.
6. The production method according to claim 5, characterized in that: the macroporous adsorption resin column involved in the process is weak-polarity macroporous adsorption resin.
7. The production method according to claim 2, characterized in that: the silica gel chromatography elution system related by the process is one or more of dichloromethane, ethyl acetate, n-butanol, methanol and petroleum ether.
8. The production method according to claim 7, characterized in that: the silica gel chromatography elution system related to the process is a dichloromethane-methanol system.
9. The production method according to claim 2, characterized in that: the recrystallization solvent involved in the process can be one or more of methanol, ethanol, acetone, ethyl acetate and chloroform.
10. The production method according to claim 9, characterized in that: the recrystallization solvent involved in the process is methanol or ethyl acetate.
11. Use of a compound according to claim 1 for the manufacture of a medicament for the treatment of rheumatoid arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610028681.1A CN106977561B (en) | 2016-01-16 | 2016-01-16 | Preparation of Sutherlandin-5-p-hydroxybenzoate and application thereof in preparation of drugs for treating rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610028681.1A CN106977561B (en) | 2016-01-16 | 2016-01-16 | Preparation of Sutherlandin-5-p-hydroxybenzoate and application thereof in preparation of drugs for treating rheumatoid arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106977561A CN106977561A (en) | 2017-07-25 |
| CN106977561B true CN106977561B (en) | 2021-04-20 |
Family
ID=59340156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610028681.1A Active CN106977561B (en) | 2016-01-16 | 2016-01-16 | Preparation of Sutherlandin-5-p-hydroxybenzoate and application thereof in preparation of drugs for treating rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106977561B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113350364A (en) * | 2020-03-06 | 2021-09-07 | 滨州医学院 | Application of pearl plum extract in preparation of medicine for preventing and treating pulmonary fibrosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2721278T3 (en) * | 2013-07-14 | 2019-07-30 | Olle Svenssons Partiaffaer Ab | Alloid compositions of the Ribes species to treat conditions associated with mitochondrial function or inhibition of pDE4, PDE5 and IKK-BETA |
-
2016
- 2016-01-16 CN CN201610028681.1A patent/CN106977561B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106977561A (en) | 2017-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113105388B (en) | Euphorbia lathyris diterpene alkyl compound and extraction method and application thereof | |
| CA2502703C (en) | A natural compound for prevention and treatment of diabetes, process for preparing the same, and pharmaceutical use thereof | |
| CN111253247B (en) | Preparation method and application of novel phenolic acid compound with anti-inflammatory activity | |
| CN111454317B (en) | Panaxadiol type triterpenoid saponin, folium Notoginseng extract, pharmaceutical composition and cosmetic composition with antiinflammatory activity | |
| CN106977561B (en) | Preparation of Sutherlandin-5-p-hydroxybenzoate and application thereof in preparation of drugs for treating rheumatoid arthritis | |
| TWI610676B (en) | Method for producing nerve cell death inhibitor, anti-Alzheimer's disease agent, anti-brain hypofunction agent, medicine having anti-Alzheimer's disease effect or anti-brain function, and nerve cell death inhibitor | |
| WO2024031997A1 (en) | N-n-bis-oxazolidinone alkaloid compounds, preparation method, and use in medical field | |
| CN107158050B (en) | Hydrangea paniculata total coumarin glycoside, preparation method, composition and application thereof | |
| CN106977560B (en) | Preparation of 2S-cardiospermin-5-benzoate and application thereof in preparation of drugs for treating rheumatoid arthritis | |
| JP3128823B2 (en) | Anticancer compound and method for producing the same | |
| CN106974924B (en) | Preparation of Isocardidiospermin-5-p-hydroxybenzoate and application thereof in preparation of drugs for treating rheumatoid arthritis | |
| CN106974923B (en) | Preparation of Sutherlandin-5-cis-p-coumarate and application thereof in preparation of medicine for treating rheumatoid arthritis | |
| CN106974922B (en) | Preparation of 2S-cardiospermin-5-cis-p-coumarate and application thereof in preparation of medicines for treating rheumatoid arthritis | |
| CN106974921B (en) | Preparation of 2R-cardiospermin-5-p-hydroxybenzoate and application thereof in preparation of drugs for treating rheumatoid arthritis | |
| CN106963766B (en) | Azaspiroanone pharmaceutical composition and preparation method thereof | |
| CN102250197B (en) | Preparation method and application of total steroidal saponin extracts of dwarf lilyturf roots | |
| CN110563688B (en) | Benzopyran compounds with anti-complement activity and application thereof | |
| CN109206392B (en) | Coumarin compound and preparation method and application thereof | |
| CN104402964A (en) | Cleistanone O-(imidazolyl) ethyl derivative, and preparation method and application thereof | |
| CN104447900B (en) | Preparation activity, application and quality control of new compound | |
| CN112500444B (en) | Compound and preparation method and application thereof | |
| JPH0481570B2 (en) | ||
| CN114409544B (en) | Phenylpropanoid with vasodilation activity, and extraction method and application thereof | |
| CN111825646B (en) | Butylphenylpeptide compound and preparation method and application thereof | |
| CN113666895B (en) | Halogenated 2-benzo [ c ] furanone compounds and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |